Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, García LF, Soto J Lorlatinib as a first-line treatment for ALK+ advanced Non-Small Cell Lung Cancer: a cost-effectiveness analysis in Spain 25th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena (Austria). 06-09 nov 2022 POSTER